← brief for 2026-09-28 · Slowing decline

Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.

Article C Peer reviewed Observational

Key takeaways

This study followed 23 adults taking lithium for bipolar disorder. They started a new drug called tirzepatide. The study looked at kidney markers over 12 months. It is observational, so it shows a link, not proof of cause. It is a small cohort.

Who did this work

Rescalli MB · Fagiolini A · Carmellini P · Pinzi M · Castaldo F · Cuomo A

Source

Article · PubMed, the drug frontier · 2026 Nov
https://pubmed.ncbi.nlm.nih.gov/42803597/